Macrolides and methods for producing same

Abstract

This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them.

1 . An actinomycete strain LL-C31037 having NRRL Accession number 30721 or an actinomycete strain BD240 having NRRL Accession number 30810.  
     
     
         2 . The isolate of a strain according to  claim 1  and derivatives, mutants, recombinants, and modified forms thereof capable of producing a compound of formula (1):  
       
         
           
           
               
               
           
         
       
     
     
         3 . A method for producing a macrolide, comprising culturing an actinomycete inoculum originating from an isolate of Actinomycete strain according to  claim 1  under conditions which permit production of the macrolide.  
     
     
         4 . A method for producing a compound comprising culturing an isolate from an actinomycete strain according to claims  1  under suitable conditions to produce a compound having formula (I).  
     
     
         5 . The method of  claim 4  further comprising isolating said compound in a substantially pure form.  
     
     
         6 . The method of  claim 5  further comprising isolating said compound by chromatography.  
     
     
         7 . The product produced by the method of  claim 4 .  
     
     
         8 . A method of treating a mammal comprising administering to said mammal a composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof  
       
         
           
           
               
               
           
         
       
     
     
         9 . A method for treatment of a neurological disorder comprising administering an effective amount of a composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof  
       
         
           
           
               
               
           
         
       
     
     
         10 . The method of  claim 9  wherein the neurological disorder is epilepsy, stroke, cerebral ischemia, cerebral palsy, Alper's disease, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, dementia with Lewy bodies, Rhett syndrome, neuropathic pain, spinal cord trauma, or traumatic brain injury.  
     
     
         11 . The method of  claim 10  wherein the neurological disorder is senile dementias, dementia with lewy bodies, mild cognitive impairment, Alzheimer's disease, or cognitive decline.